The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...

Abiraterone (Zytiga ... naïve patients with mCRPC were assigned to receive 160 mg/day of enzalutamide vs. placebo in a double blind fashion. After a median follow-up of 20 months, interim ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Aim: To identify factors predicting primary resistance to new-generation hormonal agents (NHAs), abiraterone acetate and enzalutamide in patients with castration-resistant prostate cancer (CRPC).

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases. The FDA has approved FoundationOne CDx ...

Mean fold-change in response at wk 6 over baseline.

PSMA-targeted Radioligand Therapy with 131I-LNTH-1095 Plus Enzalutamide versus Enzalutamide Alone in Chemotherapy-naïve Patients Whose Piflufolastat F 18-avid Metastatic Castration-resistant Prostate ...

NGS for metastatic adenocarcinoma of the prostate. January 24, 2025 Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with ...